Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 3, 2006, Pages 402-404

  Baumann, C R ^a   Khatami, R ^a   Werth, E ^a   Bassetti, Claudio L ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OREXIN;

ADULT; ARTICLE; CATAPLEXY; CLINICAL ARTICLE; DAYTIME SOMNOLENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; EPWORTH SLEEPINESS SCALE; FEMALE; HALLUCINATION; HUMAN; MALE; NARCOLEPSY; PARASOMNIA; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEFICIENCY; REM SLEEP; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; CATAPLEXY; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NARCOLEPSY; NEUROPEPTIDES; POLYSOMNOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SLEEP, REM;

EID: 33644525928     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.067207     Document Type: Article

References (12)

1. Baumann CR, Bassetti CL. Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. Sleep Med Rev 2005;9(4):253-68.
2. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62.
3. Dauvilliers Y, Baumann CR, Carlander B, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003;74:1667-73.
4. Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004;13:395-406.
5. American Sleep Disorders Association. International classification of sleep disorders, revised: diagnostic and coding manual. Rochester, MN: American Sleep Disorders Association, 1997.
6. Anic-Labat S, Guilleminault C, Kraemer HC, et al. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999;22:77-87.
7. Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997;20:1012-20.
8. Khatami R, Maret S, Werth E, et al. Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway. Lancet 2004;363:1199-200.
9. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002;11:91-3.
10. Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-8.
11. Aldrich MS. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996;46:393-401.
12. Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain 1997;120:1423-35.